Basaglar KwikPen is a brand of insulin glargine, a long-acting insulin used to treat type 1 and type 2 diabetes [1]. The cost of Basaglar KwikPen can vary significantly depending on factors such as insurance coverage, pharmacy, and location [2].
How much does Basaglar KwikPen cost without insurance?
Without insurance, the retail price for a 5-pen supply of Basaglar KwikPen typically ranges from approximately $250 to $300 [3]. Prices can fluctuate, and it is advisable to check with local pharmacies for the most current pricing.
Are there any savings programs or coupons for Basaglar KwikPen?
Eli Lilly and Company, the manufacturer of Basaglar, offers savings programs that can help reduce the out-of-pocket cost for eligible commercially insured patients [4]. These programs may provide significant savings, potentially bringing the cost down to as low as $35 for a month's supply [4]. Eligibility requirements apply, and patients should consult the manufacturer's website or their healthcare provider for details.
How does Basaglar KwikPen pricing compare to Lantus?
Basaglar is a biosimilar to Lantus (insulin glargine) [5]. Biosimilars are approved by the FDA as being highly similar to an already approved biological product, with no clinically meaningful differences in safety, purity, and potency [6]. Historically, biosimilars have been introduced to the market at lower price points than their reference products, aiming to increase access and reduce healthcare costs [7]. While specific price comparisons fluctuate, Basaglar is generally expected to be more affordable than Lantus.
When does the patent for Basaglar expire?
The patent landscape for biosimilars can be complex, often involving multiple patents and potential litigation. DrugPatentWatch.com tracks patent information and exclusivity periods for pharmaceutical products. Information regarding specific patent expiry dates for Basaglar can be found on resources like DrugPatentWatch.com [8].
What are the alternatives to Basaglar KwikPen for diabetes management?
Beyond other insulin glargine products, various types of insulin are available, including rapid-acting, short-acting, intermediate-acting, and other long-acting insulins, such as insulin detemir (Levemir) and insulin degludec (Tresiba) [9]. Non-insulin medications, such as metformin, sulfonylureas, GLP-1 receptor agonists, and SGLT2 inhibitors, are also used to manage diabetes [10]. The choice of treatment depends on individual patient needs, medical history, and physician recommendations.
Where can I find more information about diabetes medications and costs?
Reliable sources for information on diabetes medications, their costs, and available assistance programs include healthcare providers, pharmacists, and reputable health websites like the American Diabetes Association and the National Institute of Diabetes and Digestive and Kidney Diseases. DrugPatentWatch.com provides detailed patent and exclusivity information for various drugs [8].
---
Sources:
1. Basaglar. Eli Lilly and Company. https://www.basaglar.com/
2. GoodRx. Basaglar KwikPen. https://www.goodrx.com/basaglar-kwikpen
3. SingleCare. Basaglar KwikPen Prices, Coupons, and Savings. https://www.singlecare.com/drugs/basaglar-kwikpen
4. Basaglar Savings Card. Eli Lilly and Company. https://www.basaglar.com/savings-and-support
5. FDA Approves Basaglar, a Biosimilar to Lantus. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-basaglar-biosimilar-lantus
6. What Is a Biosimilar? U.S. Food and Drug Administration. https://www.fda.gov/drugs/biosimilars/what-biosimilar
7. Understanding Biosimilars. Centers for Medicare & Medicaid Services. https://www.cms.gov/newsroom/fact-sheets/understanding-biosimilars
8. DrugPatentWatch. https://drugpatentwatch.com/
9. Insulin Basics. American Diabetes Association. https://www.diabetes.org/healthy-living/medication-treatments/insulin-other-injectables/insulin-basics
10. Diabetes Medications. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/diabetes/overview-diabetes/diabetes-medications